Selcaxen is identified for this website as a product containing 40 mg of selpercatinib. The specific manufacturer, dosage form and authorization status require verification.

Selpercatinib is a selective RET kinase inhibitor used for selected RET-driven cancers.

RET is a receptor tyrosine kinase. Certain RET gene fusions and mutations can act as cancer-driving alterations.

Current U.S. labeling includes selected RET fusion-positive NSCLC, RET-mutant medullary thyroid cancer, RET fusion-positive thyroid cancer and certain RET fusion-positive solid tumors.

Yes. Current U.S. labeling requires selection based on the relevant RET fusion or RET mutation detected by an FDA-approved test.

Selpercatinib is a targeted kinase inhibitor rather than conventional cytotoxic chemotherapy.

It inhibits RET kinase signaling associated with abnormal RET proteins.

Current U.S. RETEVMO labeling lists 40 mg and 80 mg capsules and 40 mg, 80 mg, 120 mg and 160 mg tablets.

That should not be assumed. Selcaxen-specific formulation and dosage-form information require verification.

Current U.S. adult and adolescent regimens are administered twice daily, with pediatric dosing based on body-surface area and potentially differing in frequency.

It may generally be taken with or without food, but special instructions apply when a proton-pump inhibitor is required.

Acid-reducing agents can reduce selpercatinib exposure. Current labeling recommends avoiding them when possible and provides specific timing instructions if their use cannot be avoided.

Common reactions include edema, diarrhea, fatigue, dry mouth, hypertension, abdominal pain, constipation, nausea, rash and headache.

Yes. Hypertension is a clinically important adverse reaction and requires monitoring.

Yes. Increased ALT and AST are common laboratory abnormalities, and serious hepatotoxicity can occur.

Yes. ILD/pneumonitis can occur and may be severe, life-threatening or fatal.

Yes. Selpercatinib can cause concentration-dependent QT prolongation, requiring additional monitoring in patients at risk.

Serious, including fatal, hemorrhagic events can occur.

Tumor lysis syndrome is a recognized risk, particularly when cancer cells break down rapidly.

Selpercatinib can cause fetal harm based on animal findings. Pregnancy status should be assessed before treatment in females of reproductive potential.

Current U.S. labeling advises against breastfeeding during treatment and for one week after the final dose.

The development program was associated with Loxo Oncology, which became part of Eli Lilly.

RETEVMO is the established Lilly product containing selpercatinib and received initial U.S. approval in 2020.

The products should not be described as identical solely because they contain the same active ingredient. Product-specific formulation, manufacturing and regulatory information must be established.

Yes. Monitoring can include liver enzymes, blood pressure, ECG/QT interval, electrolytes, thyroid function and clinical assessment for pulmonary or other serious adverse reactions.

Dose interruption and reduction may be required for adverse reactions or certain drug interactions. The appropriate modification depends on the specific clinical situation.